Show simple item record

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial

dc.contributor.authorRECOVERY Collaborative Group
dc.date.accessioned2022-08-02T11:04:01Z
dc.date.available2022-08-02T11:04:01Z
dc.date.issued2022-02-18
dc.identifier218527331
dc.identifier5a725d50-3f99-4e17-900f-87e95f34ad54
dc.identifier35151397
dc.identifier85124302599
dc.identifier.citationRECOVERY Collaborative Group 2022 , ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ' , The Lancet , vol. 399 , no. 10325 , pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5en
dc.identifier.issn0140-6736
dc.identifier.otherPubMedCentral: PMC8830904
dc.identifier.otherORCID: /0000-0002-1397-4272/work/116747543
dc.identifier.urihttps://hdl.handle.net/2164/18986
dc.descriptionAcknowledgments The RECOVERY trial is supported by grants to the University of Oxford (Oxford, UK) from UK Research and Innovation (UKRI; Medical Research Council) and the National Institute of Health Research (NIHR; MC_PC_19056), the Wellcome Trust (222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC_UU_00002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Tocilizumab was provided free of charge for this trial by Roche Products. Regeneron Pharmaceuticals supported the trial through provision of casirivimab and imdevimab. The views expressed in this publication are those of the authors and not necessarily those of the UK National Health Service, the NIHR, the Department of Health and Social Care, or Regeneron Pharmaceuticals. We would like to thank the thousands of patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 177 NHS hospital organisations across the whole of the UK, supported by staff at the NIHR Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage at University of Swansea, NHS Blood & Transplant and the NHS in England, Scotland, Wales, and Northern Ireland.en
dc.format.extent12
dc.format.extent1062375
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntibodies, Monoclonal, Humanized/adverse effectsen
dc.subjectAntibodies, Viral/blooden
dc.subjectAntiviral Agents/adverse effectsen
dc.subjectCOVID-19/drug therapyen
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectHospitalizationen
dc.subjectHumansen
dc.subjectInfusions, Intravenousen
dc.subjectMaleen
dc.subjectSARS-CoV-2/immunologyen
dc.subjectTreatment Outcomeen
dc.subjectR Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectMC_PC_19056en
dc.subjectMC_UU_00002/14en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subjectNIHR-SRF-2015-08-001en
dc.subjectWellcome Trusten
dc.subject222406/Z/20/Zen
dc.subject.lccRen
dc.titleCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1016/S0140-6736(22)00163-5
dc.identifier.vol399en
dc.identifier.iss10325en


Files in this item

Thumbnail
Name:
Recovery_etal_TL_Casirivimab_A ...
Size:
1.013Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record